Applications of Fluvastatin in Industrial Manufacturing

As a dedicated producer of Fluvastatin, we supply the pharmaceutical manufacturing sector with consistently high-quality raw material tailored to the rigorous requirements of downstream processing. Our production integrates targeted specifications and validated quality protocols, ensuring suitability across all relevant industrial applications. Fluvastatin’s primary market lies within the statin class of APIs, limiting its use to distinctive, compliant pharmaceutical sectors. Below, we outline the principal downstream domains where Fluvastatin is directly integrated, covering each application’s compliance, formulation range, processing method, and end product formats.

1. HMG-CoA Reductase Inhibitor API Production for Branded and Generic Tablets

Fluvastatin serves as the central active ingredient in cardiovascular pharmaceuticals, primarily targeting hypercholesterolemia and mixed dyslipidemia. Leading pharmaceutical manufacturers incorporate our material during synthesis and granulation steps for their branded and generic sustained-release and immediate-release oral solid dosage forms. Adjustments to particle size distribution support high-speed tablet compression, while trace impurity controls meet global regulatory limits.

Industry compliance standards

• EU EMA monograph for Fluvastatin Sodium
• United States Pharmacopeia (USP) Fluvastatin Sodium specification
• Chinese Pharmacopoeia (ChP)
• Current Good Manufacturing Practice (cGMP) for Active Pharmaceutical Ingredients (APIs)

Typical usage ratio

• 5% to 12% of tablet core mass, depending on target strength (usually 20 mg to 80 mg per tablet)
• Formulation adjusted for excipient compatibility, dissolution profile, and final hardness

Downstream process integration

• Direct addition to mixer during wet or dry granulation phase
• In-process blending with microcrystalline cellulose, lactose, and superdisintegrants
• Screened pre-compression for uniform content distribution

Final product types

• Branded Fluvastatin tablets (20 mg, 40 mg, 80 mg strengths)
• Generic Fluvastatin sodium oral tablets
• Bilayer cardiovascular therapy tablets

2. Capsule Dosage Form Production for Global Pharmaceutical Markets

Leading oral capsule manufacturers rely on the raw material's flow properties and purity for hard gelatin and HPMC capsule filling lines. Precise control of particle uniformity allows high-speed encapsulation, maintaining dose accuracy and minimizing batch rejections under automated visual inspection. Formulation adapts for various excipient matrices to meet regulatory expectations for dissolution and bioavailability.

Industry compliance standards

• ICH Q7 GMP guidance
• Pharmacopoeia Europea (Ph. Eur.) regulations for statin capsules
• US FDA Quality by Design (QbD) requirements
• WHO Prequalification Programme for finished dosage forms

Typical usage ratio

• 6% to 15% of capsule fill weight, according to capsule size and market authorization specifications
• Fluctuations controlled via in-process analytical assays and filling machine calibration

Downstream process integration

• Incorporated during initial powder blend step for powder-in-capsule systems
• Dry mixing with mannitol, starch, and magnesium stearate to ensure low moisture content
• Loaded directly into automated capsule filling hoppers under inert atmosphere as required

Final product types

• Immediate-release Fluvastatin hard gelatin capsules (20 mg/40 mg/80 mg)
• Extended-release HPMC capsules for international generic registrations
• Combination capsules containing Fluvastatin and antihypertensive agents (co-formulated)

3. Bulk API Integration for Hospital Compounding and Ex-Tempore Preparations

Hospital-based compounding facilities and ex-tempore formulation providers purchase our API under validated bulk conditions to prepare custom oral and liquid formulations for patient-specific needs, including dose adjustment and alternative delivery forms for pediatric or dysphagic populations. Uniquely, these use cases strictly require documentation supporting traceable GMP manufacturing and full impurity profiling at multi-kilogram scale, along with real-time release testing results.

Industry compliance standards

• EU GMP for Compounded Preparations (Directive 2001/83/EC, Annex 13)
• USP General Chapter <795> for Nonsterile Compounding
• Local hospital pharmacy QA standards and ISO/IEC 17025-accredited laboratory testing
• Formal batch certification and Certificate of Analysis (CoA) supplied with each shipment

Typical usage ratio

• Individualized, ranging from 0.05% up to 2% by total preparation weight, titrated to patient prescription
• Excipients and mediums (syrup bases, suspending agents) adjusted by compounding pharmacist

Downstream process integration

• Reconstitution into suspension or syrup bases in sterile or cleanroom environments as required
• Mixing into oral solution/vehicle at point of dispensing utilizing volumetric or gravimetric tools
• Finished aliquots dispensed in calibrated, sealed amber containers for direct administration

Final product types

• Oral Fluvastatin suspension (compounded, dose-flexible)
• Alcohol-free ex-tempore syrup for pediatric use
• Patient-specific liquid formulations for hospital and home care settings

4. Reference Standard Supply for Pharmacopoeial Testing Laboratories

Accredited analytical labs and finished-dose manufacturers regularly require reference-grade Fluvastatin with batch-specific purity profiles and impurity markers for system suitability testing, calibration curves, and stability program support. Only Fluvastatin meeting precise spectroscopic and chromatographic benchmarks specified by monographs can serve as a reference standard, and shipments must include traceable raw data and batch certification to facilitate international laboratory accreditation processes.

Industry compliance standards

• USP Reference Standard program quality criteria
• Pharmacopoeia Europea (Ph. Eur.) CRS (Chemical Reference Substances) program
• ISO/IEC 17025 laboratory accreditation for pharmaceutical testing
• ICH Q3A/B guidance on impurities and residual solvents

Typical usage ratio

• Microgram to milligram quantities, typically 0.5–5 mg per system suitability solution or calibration curve setup
• Exact measurement determined by validated HPLC or LC-MS protocols

Downstream process integration

• Direct solution or solid aliquot preparation for analytical instrument calibration
• Routine identity and content assays for batch release testing in QC labs
• Stability study spiking in ongoing product shelf-life programs

Final product types

• Pharmacopoeial and in-house certified reference standards
• Quality control validation kits supplied to QC and R&D laboratories worldwide
• Calibration solutions used in regulatory submission dossiers